IRRAS presents new financial targets
Stockholm, March 6, 2019 – IRRAS AB (Nasdaq First North Premier: IRRAS), a commercial-stage medical science and technology company, today announced that its board has resolved to revise the company’s financial targets. The financial targets that will apply effective today are: - Revenue exceeding SEK 275 million in 2021- Gross margin exceeding 72 % in 2021- Cash-flow positive by Q4 2021 “IRRAS has worked hard to build the foundations for growth, and we are optimistic in our ability to continue to develop innovative products that will change the lives of millions,” said